NCT00219193

A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients

An Eight Week, Multicenter Study to Evaluate Efficacy and Safety of the Triple Combo of Aliskiren /Valsartan/HCTZ (300/320/25 mg), Compared to the Double Combos of Aliskiren/HCTZ (300/25 mg) or Valsartan/HCTZ (320/25 mg) in Patients With Essential Hypertension Not Adequately Responsive to HCTZ 25 mg

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 641 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the blood pressure lowering effect and safety of the triple combination aliskiren / valsartan / HCTZ (300/320/25 mg) in patients with essential hypertension not adequately responsive to HCTZ 25 mg

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	aliskiren

Timeline

• Start date: 2005-10-01
• Primary completion: 2007-01-01
• Completion: 2007-01-01
• First posted: 2005-09-22
• Last updated: 2017-02-07

Locations

2 sites across 2 countries: United States, Germany